After grappling with operational challenges in the post-pandemic period, U.S. healthcare giant CVS Health (CVS) is now demonstrating a robust recovery trajectory. Over the past 12 months, the company’s stock price has rallied 48%, and multiple market analysts believe this rebound may be just getting started. CVS Health is improving its operational quality through cost control, business optimization, and digital operations. The company’s diversified business model and vertical integration strategy provide support for its long-term growth. Against the backdrop of continuously improving fundamentals, stable dividend returns, and valuation still below the industry average, CVS Health is well-positioned to continue receiving market revaluation, and its medium-to-long-term investment value warrants attention.
CVS Health faced multiple challenges after the pandemic: sales of pandemic-related products (such as diagnostic tests) declined sharply, while utilization and costs in its health insurance business, particularly in the Medicare Advantage segment, continued to rise, leading the company to lower its earnings guidance on multiple occasions. However, over the past year, the company’s financial condition has been steadily improving.
In the first-quarter earnings report this year, CVS Health’s revenue grew approximately 6% year-over-year to $100.4 billion, and adjusted earnings per share rose to $2.57, representing a year-over-year increase of about 14%. The company also raised its EPS guidance for fiscal year 2026, and the quarterly results exceeded analysts’ expectations, delivering a standout performance of “raising guidance plus beating estimates.”
The earnings improvement is mainly attributed to two factors: First, the company’s Medical Benefit Ratio (MBR) dropped to 84.6% in the first quarter, down 2.7 percentage points from the same period in 2025. The MBR measures the proportion of premium income used for members’ medical expenses, and a decline in this ratio signifies higher profitability. Second, CVS Health improved the operational efficiency of its insurance business through digital authorization and approval processes, effectively controlling costs.
CVS Health plans to scale back its Medicare Advantage business this year, which may lead to an overall revenue decline, but the company intends to focus on profitable growth. In the long run, the company’s diversified healthcare business layout covers multiple aspects of the patient care journey, including primary care, insurance services, and pharmacy operations, offering patients a convenient one-stop service experience.
In terms of shareholder returns, CVS Health has increased its dividends by a cumulative 56.5% over the past decade, and its current forward dividend yield stands at 2.6%.
Despite the significant stock price rebound, CVS Health’s valuation remains attractive. The company’s current forward price-to-earnings ratio is approximately 13.8 times, below the healthcare sector average of 17.4 times.
On June 8, Mizuho analyst Ann Hynes reiterated her bullish rating on CVS Health and raised the price target by 4.5% to $115 per share. Based on the stock price of approximately $97 at the time, this implied an upside of about 18.5%. Even after the recent stock price appreciation, the target price still suggests a potential upside of roughly 13%.
Currently, CVS Health’s stock price corresponds to expected EPS of $7.43 for 2026, with a forward P/E of about 13.8 times. If the stock price reaches $115, the forward multiple would rise to approximately 15.5 times. Analysts point out that the market has fully recognized CVS Health as a diversified healthcare services company similar to UnitedHealth Group, whose forward valuation has already been revalued to the low 20s. Given market expectations for double-digit earnings growth at CVS Health in 2027, if its forward P/E approaches 20 times, the stock price could potentially reach around $150 per share.
